Abstract
Abstract Studies have been conducted to identify early in vivo products of normal fibrinogen catabolism, focusing on 2 normal variants: (1) the high solubility, low molecular weight (269,000) fibrinogen (LMWF) of Mosesson and co-workers 3 and (2) the cryofibrinogen/fibrin complex (cryoprofibrin) characterized by Shainoff and Page. 5 In normal rabbits, LMWF has been demonstrated to be derived in vivo from the low solubility, high molecular weight fibrinogen (HMWF) which is the bulk of the plasma pool. 1 In the present study, 125 I-HMWF was injected into normal rabbits and the gradual appearance of radioactivity noted not only in the LMWF, but also in cryoprofibrin. By day 2 the specific activity of cryoprofibrin equaled that of HMWF, and by day 3 the specific activity of LMWF equaled that of HMWF. Thereafter, the specific activities of cryoprofibrin and LMWF slightly exceeded that of HMWF. The HMWF t12 was 47 hours, and total fibrinogen t12 was 6312 hours. In separate experiments, the t12 of 125 I-LMWF and 125 I-cryoprofibrin were 2612 and 13 hours, respectively. These studies support a concept of several normal catabolic pathways for fibrinogen (1) by low grade proteolysis to LMWF and (2) limited, partial, soluble, fibrin formation (cryoprofibrin). There is indirect evidence to suggest these processes also occur in man.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
